Harmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
Follow HRMY
Harmony Biosciences Holdings, Inc. (HRMY) EV/Sales
As of 16 October 2026, Harmony Biosciences Holdings, Inc. (HRMY) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from 0.0× (December 2020) to 9.8× (June 2021); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.8× | (24.10%) |
| FY2024 | 2.3× | (18.65%) |
| FY2023 | 2.9× | (58.13%) |
| FY2022 | 6.9× | (13.13%) |
| FY2021 | 7.9× | 40.52% |
| FY2020 | 5.6× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.7× | 31.40% |
| Mar 2026 | 1.3× | (28.65%) |
| Dec 2025 | 1.8× | 35.33% |
| Sep 2025 | 1.3× | (28.87%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IRON Disc Medicine, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | 1.1× |
| HRMY Harmony Biosciences Holdings, Inc. | 1.8× |
| NVAX Novavax, Inc. compare | 3.4× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.6× |
| VRDN Viridian Therapeutics, Inc. compare | 18.6× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 23.7× |
| SLS SELLAS Life Sciences Group, Inc. compare | 167× |
| CLDX Celldex Therapeutics, Inc. compare | 1,610× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)